News For AZN From The Last 14 Days Check below for free stories on AZN the last two weeks.
There are 12 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 9, 2010
|
| 05:57 EDT |  | AZN |
| theflyonthewall.com: | AstraZeneca receives FDA approval for new Crestor indication | | AstraZeneca announced that the FDA has approved CRESTOR to reduce the risk of stroke, heart attack, and arterial revascularization procedures in individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease based on age, high-sensitivity C-reactive protein greater than or equal to 2 mg/L, and the presence of at least one additional CVD risk factor, such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease. :theflyonthewall.com |
|
|
February 5, 2010
|
| 07:41 EDT |  | AZN |
|
|
February 4, 2010
|
| 07:11 EDT | | AZN |
| theflyonthewall.com: | Pfizer to reduce R&D as it absorbs Wyeth, WSJ reports | | Pfizer (PFE) plans to cut its R&D spending by up to $3B by 2012, which was more than 25% of the combined R&D of Pfizer and newly acquired Wyeth in 2008, reports the Wall Street Journal. The move is based on efficiencies without hurting future product development. Reference Link :theflyonthewall.com |
|
|
January 29, 2010
|
| 14:08 EDT | | AZN |
|
|
January 28, 2010
|
| 09:32 EDT |  | AZN |
| | 09:28 EDT | | AZN |
| | 09:27 EDT | | AZN |
| | 09:26 EDT | | AZN |
| | 09:26 EDT | | AZN |
| | 09:24 EDT | | AZN |
| theflyonthewall.com: | AstraZeneca announces reduction of around 1,800 positions | | AstraZeneca said it will undertake additional restructuring within the R&D function, including a reduction in the number of disease area targets within our core therapeutic areas. By 2014, annual savings of $1 billion should be realized; of which one-half is estimated to be cost savings and the other half cost avoidance. Based on preliminary estimates, approximately 3,500 positions may be affected by this program. After taking account of positions that will be retained whilst being relocated to another site, the investment in new skills and capabilities and further expansion of our Biologics activities, the net reduction may be around 1,800 positions. The cost of this restructuring is estimated to be $1 billion, of which approximately 60 percent will be cash costs. :theflyonthewall.com |
| | 07:04 EDT | | AZN |
| | 07:00 EDT | | AZN |
| theflyonthewall.com: | AstraZeneca reports Q4 EPS $1.07 vs. consensus of $1.52 | | Reports Q4 revenue $8.95B vs. consensus of $8.85B :theflyonthewall.com |
|
|
|
Subscribe for More Information